• Quantifying Drug Responses: Innovations in In Vitro Cancer A

  2026-05-07

  Schwartz’s dissertation introduces a refined framework for measuring anti-cancer drug responses, distinguishing between proliferative arrest and cell death in vitro. This approach enhances the accuracy of preclinical cancer drug evaluation and has important implications for mechanistic studies, including research on survivin inhibitors.

• Cytoskeleton-Dependent Autophagy Under Mechanical Stress: In

  2026-05-06

  This study delineates how the cytoskeleton, especially microfilaments, is indispensable for autophagy induced by compressive mechanical stress in human cell lines. By dissecting the relative contributions of microfilaments and microtubules, the authors provide mechanistic clarity with practical implications for research in mechanotransduction, redox biology, and apoptosis.

• Forsythoside E: A PKM2 Inhibitor Empowering Immunometabolic

  2026-05-06

  Forsythoside E, a phenolic acid glycoside from Forsythia suspensa, revolutionizes macrophage metabolism assays by directly promoting PKM2 tetramerization and M2 polarization. Its robust biophysical properties, high binding specificity, and validated workflow parameters give researchers a reproducible edge in sepsis-induced liver injury and advanced immunometabolic studies.

• Lamotrigine: Applied Protocols for Sodium and 5-HT Pathway R

  2026-05-05

  Lamotrigine’s dual action as a sodium channel blocker and serotonin (5-HT) inhibitor offers advanced versatility for in vitro epilepsy and cardiac current modulation assays. With high-purity sourcing from APExBIO, this guide details actionable protocols, troubleshooting strategies, and critical workflow decisions—anchored in recent CYP19 inhibition findings.

• Laminin (925-933): Precision Peptide for Advanced Cell Migra

  2026-05-05

  Explore how Laminin (925-933), a laminin B1 chain peptide, enables advanced cell migration and chemotaxis studies with unmatched specificity. This article uniquely bridges its functional domain targeting with emerging neurodegenerative research, providing new perspectives beyond existing reviews.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-04

  Schwartz's dissertation critically re-examines how in vitro assays measure cancer drug responses, distinguishing between proliferative arrest and cell death. By clarifying the limitations and interpretive differences of viability metrics, this work informs more accurate preclinical assessment methods and highlights the necessity for refined approaches in autophagy and cancer biology research.

• Sulfaphenazole Restores Vascular Function in Diabetic Mice

  2026-05-04

  This study demonstrates that Sulfaphenazole, a CYP2C9 inhibitor, restores endothelium-dependent vasodilation in a diabetic mouse model by reducing oxidative stress and increasing nitric oxide bioavailability. The findings highlight a mechanistic link between cytochrome P450-derived superoxide production and vascular dysfunction in diabetes, supporting the translational value of CYP2C inhibition for vascular endothelial function research.

• Z-VAD-FMK: Optimizing Apoptosis Inhibition for Advanced Rese

  2026-05-03

  Z-VAD-FMK (SKU A1902) from APExBIO empowers bench scientists to dissect and modulate apoptotic pathways with unmatched specificity and reproducibility. This guide bridges reference-driven insights, hands-on protocol enhancements, and troubleshooting strategies, ensuring superior results in apoptosis inhibition and caspase activity measurement across diverse research models.

• Norovirus Exploits NINJ1 for Selective Viral Protein Secreti

  2026-05-02

  This study uncovers how murine norovirus hijacks the host membrane protein NINJ1 to selectively secrete its NS1 protein, a process requiring caspase-3 cleavage and bypassing classical secretion pathways. The findings redefine the regulatory landscape of programmed cell death and protein export, with implications for understanding viral immune evasion and apoptosis-linked secretion.

• Vorinostat: Empowering Epigenetic Modulation in Oncology Res

  2026-05-01

  Vorinostat (SAHA) stands at the forefront of HDAC inhibition, enabling precise dissection of chromatin remodeling and intrinsic apoptosis in cancer biology research. This article distills cutting-edge workflows, troubleshooting strategies, and actionable insights—directly translating bench discoveries into robust experimental outcomes.

• Imipramine: Tricyclic Antidepressant in Autophagy & Apoptosi

  2026-05-01

  Imipramine, a classic tricyclic antidepressant, is fueling innovation in cancer, neuroprotection, and immunology research by modulating autophagy and apoptosis pathways. This article delivers actionable workflows, comparative insights, and troubleshooting tips to maximize the scientific impact of Imipramine from APExBIO.

• Tapuy Lees Suppress Neurodegeneration in C. elegans Disease

  2026-04-30

  Remucal et al. (2025) demonstrate that fermentation by-products from Philippine Tapuy rice wine, specifically its lees, significantly attenuate amyloid-beta toxicity and dopaminergic neurodegeneration in C. elegans models of Alzheimer’s and Parkinson’s diseases. Their findings highlight the potent antioxidant activity of Tapuy lees and suggest novel avenues for neuroprotective therapeutic development using food-derived compounds.

• CAY10499 in Immunometabolic Research: Beyond Lipase Inhibiti

  2026-04-30

  Explore how CAY10499, a potent inhibitor of human hormone sensitive lipase, enables advanced immunometabolic research by bridging lipid metabolism and macrophage biology. Discover unique assay strategies and insights distinct from previous content.

• Letrozole: Non-Steroidal Aromatase Inhibitor in Bench Resear

  2026-04-29

  Letrozole’s precision as a non-steroidal aromatase inhibitor enables robust estrogen pathway modulation for breast cancer and neuroendocrine research. This article details actionable protocols, troubleshooting insights, and comparative advantages, drawing on advanced literature and APExBIO’s product expertise.

• Degarelix Acetate: Selective GnRH Receptor Antagonist for Pr

  2026-04-29

  Degarelix acetate is a potent, highly selective GnRH receptor antagonist used for rapid, sustained suppression of testosterone in advanced prostate cancer and experimental models. It demonstrates high receptor specificity and rapid action, with well-characterized in vitro and in vivo efficacy (source: https://doi.org/10.1262/jrd.2020-035).

464 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page